Dibromodulcitol (NSC-104800) compared with cyclophosphamide (NSC-26271) as remission maintenance therapy in previously treated children with acute lymphoblastic leukemia or acute undifferentiated leukemia: possible effectiveness in reducing the incidence of central nervous system leukemia.
Dibromodulcitol and cyclophosphamide are both alkylating agents. In this study, these two drugs were compared for their effectiveness as remission maintenance therapy for childhood acute lymphoblastic leukemia or acute undifferentiated leukemia. Toxic effects were similar in both groups of patients although cystitis did not occur with the dibromodulcitol treatment. The duration of remission was slightly shorter for dibromodulcitol than for cyclophosphamide (P = 0.04). There was, however, a lower incidence of CNS leukemia in the patients treated with dibromodulcitol, which did not seem to be related to a basic difference in the patient groups.
D001772:Blood Cell Count; D002493:Central Nervous System Diseases / Q000209:etiology / Q000517:prevention & control*; D002648:Child; D002986:Clinical Trials as Topic; D003520:Cyclophosphamide / Q000627:therapeutic use*; D006801:Humans; D007938:Leukemia / Q000150:complications / Q000188:drug therapy*; D007945:Leukemia, Lymphoid / Q000150:complications; D008936:Mitolactol / Q000627:therapeutic use*; D011241:Prednisone / Q000627:therapeutic use; D012075:Remission, Spontaneous; D014750:Vincristine / Q000627:therapeutic use
D014750:Vincristine; D003520:Cyclophosphamide; D008936:Mitolactol; D011241:Prednisone